Psoriatic Arthritis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Psoriatic Arthritis: An Unwanted Partnership - Medscape



Psoriatic Arthritis: An Unwanted Partnership 
Medscape
Once considered a rare, even benign condition, psoriatic arthritis (PsA) is the most common coexisting condition associated with psoriasis and develops in up to 30% of patients with the autoimmune disorder. On average, PsA appears 10 years after onset ...

 


Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes - Rheumatology Advisor



Rheumatology Advisor
 
Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes 
Rheumatology Advisor
Nearly one-third of patients with psoriatic arthritis (PsA) have comorbid hyperuricemia (HUC), particularly those with longer disease duration and obesity, and they are at risk of developing metabolic syndrome, according to the results of a recent ...
Psoriatic Arthritis Market Treatment Guidelines, Differences Epidemiology Patterns and Consulting Services MilTech

all 3 news articles » 


How I Learned to Outrun My Psoriatic Arthritis - Everyday Health, Inc. (blog)



Everyday Health, Inc. (blog)
 
How I Learned to Outrun My Psoriatic Arthritis 
Everyday Health, Inc. (blog)
Jared Pasparage won't let psoriatic arthritis slow him down. He started running in 2012 and has racked up 7,389 miles in those five years. ?Running for me is a barometer of accomplishment,? says Pasparage. ?It's something you accomplish that brings a ...

 


Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis 
Rheumatology Advisor
Patients with well-established psoriatic arthritis (PsA) without symptoms or a diagnosis of coronary artery disease (CAD) had a higher coronary plaque burden compared with healthy control patients, which may be associated with underlying disease ...

 


Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis 
Rheumatology Advisor
The modified minimal disease activity measures were the most stringent targets for low disease activity in patients achieving the target in terms of residual disease on joints, psoriasis, and enthesitis. The addition of C-reactive protein, however, did ...

 


Juvenile Arthritis Frustration: 'Kids Can't Get Arthritis' and Other ... - Juvenile Arthritis News



Juvenile Arthritis Frustration: 'Kids Can't Get Arthritis' and Other ... 
Juvenile Arthritis News
I was a polite kid, for the most part. My parents regularly received compliments on my behavior. To my teachers, I was always ?a pleasure to have in class,? and my friends' parents loved having me over for dinner. However, it wasn't too hard to get on ...

and more » 


Endothelium Function in AS Improved with Methotrexate Alone or Combined with Anti-TNF Agents, Study Finds - Ankylosing Spondylitis News



Endothelium Function in AS Improved with Methotrexate Alone or Combined with Anti-TNF Agents, Study Finds 
Ankylosing Spondylitis News
Sixty-four patients had rheumatoid arthritis, 29 had psoriatic arthritis, and 20 had ankylosing spondylitis. Study participants received either a monotherapy of methotrexate or a combination of methotrexate and anti-TNF. ?We evaluated changes in the ...

 


Update: 2017 Treat-to-Target Recommendations for Spondyloarthritis - Rheumatology Advisor



Rheumatology Advisor
 
Update: 2017 Treat-to-Target Recommendations for Spondyloarthritis 
Rheumatology Advisor
A 2017 clinician task force has updated recommendations from 2012 regarding therapeutic targets for axial and peripheral spondyloarthritis (SpA) ? including psoriatic arthritis (PsA) ? based on a literature review and expert opinion. The ...

 


Novartis Goes 2?0 Against J&J in Psoriasis Treatment - P&T Community



PharmaTimes
 
Novartis Goes 2?0 Against J&J in Psoriasis Treatment 
P&T Community
During an investor day in November, Novartis estimated the global market for spondylarthritis, which includes psoriatic arthritis and ankylosing spondylitis patients, was $9 billion in 2016. To be fair, J&J isn't sitting idle. While the CLEAR and ...
Novartis' Cosentyx beats J&J's Stelara in psoriasis trial PharmaTimes
Novartis new data reinforces superiority of Cosentyx® versus ... GlobeNewswire (press release)

all 7 news articles » 


Ad Com March 8 for Pfizer's Xeljanz for ulcerative colitis - Seeking Alpha



Ad Com March 8 for Pfizer's Xeljanz for ulcerative colitis 
Seeking Alpha
The FDA's Gastrointestinal Drugs Advisory Committee will meet on March 8 to discuss Pfizer's (NYSE:PFE) marketing application seeking approval for XELJANZ (tofacitinib) for adult patients with moderately-to-severely active ulcerative colitis (UC) who ...